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Abstract IgG4 is the least abundant subclass of IgG in nor-
mal human serum, but elevated IgG4 levels are triggered in
response to a chronic antigenic stimulus and inflammation.
Since the immune system is exposed to tumor-associated an-
tigens over a relatively long period of time, and tumors noto-
riously promote inflammation, it is unsurprising that IgG4 has
been implicated in certain tumor types. Despite differing from
other IgG subclasses by only a few amino acids, IgG4 pos-
sesses unique structural characteristics that may be responsi-
ble for its poor effector function potency and immunomodu-
latory properties. We describe the unique attributes of IgG4
that may be responsible for these regulatory functions, partic-
ularly in the cancer context. We discuss the inflammatory
conditions in tumors that support IgG4, the emerging and
proposed mechanisms by which IgG4 may contribute to
tumor-associated escape from immune surveillance and impli-
cations for cancer immunotherapy.
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CDRs Complementarity determining regions
CH Constant domain
Fab Fragment antigen binding
Fc Fragment crystallizable
HL Heavy chain/light chain half molecule
CSR Class switch recombination
SHM Somatic hypermutation
AID Activation-induced cytidine deaminase
IL Interleukin
VEGF Vascular endothelial growth factor
FcγR Fcγ receptor
FAE Fab-arm exchange
CDC Complement dependent cytotoxicity
ADCC Antibody-dependent cellular cytotoxicity
ADCP Antibody-dependent cellular phagocytosis
Introduction
IgG Structure
The four human IgG subclasses were discovered in the 1960s
and named according to their time of discovery and order of
their relative abundance in human serum (approximately
IgG1, 61 %; IgG2, 32 %; IgG3, 4 %; and IgG4, 3 %) [1,
2•]. IgGs are heterotetrameric glycoproteins composed by
two identical light chains and two identical heavy chains.
Each chain comprises a series immunoglobulin domains [3].
Heavy chains (γ1, γ2, γ3, or γ4, ∼50 kDa) are composed of
an N-terminal variable domain (VH) followed by three con-
stant domains (CH1, CH2, and CH3). Light chains (κ or λ,
∼25 kDa) are composed of an N-terminal variable domain
(VL) and a constant domain (CL).
Light chain VL and CL domains are paired with heavy
chain VH and CH1 domains, respectively, to form the fragment
antigen-binding (Fab) arms. The complementarity-
determining regions (CDRs) from the VH and VL domains
form the antigen-binding site. Between the CH1 and CH2 do-
mains lies the flexible hinge, which connects the Fab to the
fragment crystallizable (Fc) region, comprising CH2 and CH3
domains. The Fc region is involved in antibody effector func-
tions, engaging complement or FcγRs to trigger activation of
immune effector cells. The two light/heavy chain (HL) pairs
are joined to form the whole antibody through covalent and
non-covalent interactions between the heavy chains (Fig. 1a).
IgG4 contains unique structural features in the hinge, CH2
and CH3 domains, that are thought to be responsible for its
structural properties, binding characteristics and reduced ef-
fector function, compared to other subclasses.
IgG Production by B Cells and Class Switching
Proliferating B cells undergo class switch recombination (CSR),
enabling them to produce antibodies with the same antigen
specificity, but different isotypes (and subclasses), with different
Fc regions, and consequently different effector functions. This
affords the flexibility to develop a variety of immune responses
against the same target, immediately upon antigenic stimulation
or in a temporal manner. CSR entails intra-chromosomal DNA
recombination between the region located downstream the Var-
iable Diversity Joining segments (VDJ) region (that encode VH)
and the region upstream (a specific CH gene). The process is
triggered by the enzyme activation-induced cytidine deaminase
(AID). CSR occurs when B cells are stimulated by Tcells in the
germinal centers, and the switch toward one specific class is
dependent on the cytokine milieu in the B cell microenviron-
ment [4]. Isotype switching to both IgG4 and IgE is known to be
promoted by Th2-type cytokines (IL-4, IL-13) and by B and T
cell interaction through CD40:CD40-ligand [5, 6]. While in the
so-called Th2-biased response, biased expression of the cyto-
kines IL-10, VEGF, [6, 7], IL-12 [8], and IL-21 [8, 9] have been
reported to skew class switching toward IgG4.
Fig. 1 Structural and functional features of IgG4. a IgG4 structure: (i)
IgG architecture. The Fab comprises VH, VL, CH1, and CL domains. The
Fc region comprises CH2 and CH3 domains, and the hinge connects the
Fab to the Fc. In IgG1, two disulfide bonds (black lines) covalently link
the two heavy chains. (ii) The core hinge. In IgG1, residues 226–229 from
the core hinge are CPPC. Inter-heavy chain disulfide bonds form between
Cys226 and Cys229 (blue lines). Residues 226–229 are CPSC. In
addition to the hinge disulfide bond pattern in IgG1, intra-heavy chain
disulfide bonds can form between Cys226 and Cys229 (orange lines).
(iii) Structure of the IgG CH2 domain. The IgG1 and IgG4 CH2 domains
are colored in pink and blue, respectively. While the overall fold of the
CH2 domains is similar, in IgG4, the CH2 domain FG loop adopts a
unique conformation. (iv) Crystal structure of the IgG4-Fc region. The
two heavy chains are colored in blue and orange. Arg409, positioned at
the interface of the CH3-CH3 domain dimer, is colored in red. b Proposed
mechanisms of IgG4 blockade in cancer. Tumor-associated humoral
immunity could promote tumor suppression or progression (left and
right of dotted line, respectively). Rapid production of anti-tumor IgG1
can eliminate antigen-expressing tumor cells through CDC, ADCC, and
ADCP. Chronic antigen persistence along with a Th2-biased cytokine
milieu (IL-4, IL-10, VEGF) expressed by resident Tregs and tumor
cells can support sequential CSR of B cells to IgG4. IgG4 might thus
be more affinity matured than clonally related IgG1 and may compete
with IgG1 for binding tumor antigens. IgG4 could also undergo Fab-arm
exchange with other IgG4s, resulting in functionally monovalent
antibodies or antibodies with increased avidity. Inability of IgG4 to fix
complement and to bind activating FcγRs on immune effector cells may
result in blockade of antibody-mediated CDC, ADCC, and ADCP.
Alternatively, binding of IgG4 to the inhibitory FcγRIIb with higher
affinity than other IgG subclasses could form ICs together with other
antibodies, such as IgG1, co-engaging FcγRIIb and activating FcγRs,
dampening FcγR-mediated functions. Also, in the proteolytic
conditions of tumor microenvironments (e.g., MMP), IgG1 bound to
tumors could be cleaved on one heavy chain, causing partial
dissociation and facilitating IgG4-Fc binding. This could interfere with
IgG1-mediated effector functions or trigger intracellular uptake and
clearance of the target from tumor cell surfaces
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Binding Characteristics of IgG Subclasses for Fcγ
Receptors
Human FcγRs are expressed in different immune cells subsets
(Table 1) [10–12] and can be divided into two groups depend-
ing on their ability to bind monomeric IgG (high-affinity
receptors) or exclusively IgG immune complexes (IC) (low-
affinity receptors) [13]. There are three families of FcγRs.
FcγRI (CD64) is the only high-affinity receptor. The other
two families comprise the low-affinity receptors, FcγRII
(CD32) and FcγRIII (CD16). The FcγRII family comprises
FcγRIIa, FcγRIIb ,and FcγRIIc, while the FcγRIII family
comprises FcγRIIIa and FcγRIIIb [10]. FcγRs are function-
ally divided into activating and inhibitory receptors. All the
receptors have activating properties except FcγRIIb which is
inhibitory, and FcγRIIIb whose function is uncertain. The
affinity of IgG4 for FcγRI is of the same order of magnitude
as IgG1 and IgG3, while IgG4 binds to the other activating
receptors with lower affinity. The affinity of IgG4 for the
inhibitory FcγRIIb is similar or even higher than that of the
other subclasses (Table 1) [12].
The poor affinity of IgG4 for the activating receptors, ex-
cept FcγRI, results in an impaired ability to engage immune
effector cells compared to IgG1, its characteristics and its rel-
evance in cancer are discussed in this review [14].
Characteristics that Give IgG4 Distinct Binding
and Functional Properties
Although the constant heavy chain regions of different IgG
subclasses share over 95 % sequence homology, their struc-
tures and effector functions differ. IgG4 in particular has
unique characteristics that may be responsible for its anti-
inflammatory properties and less potent effector function
compared with IgG1 and IgG3 [15]. Throughout this review,
amino acids are indicated using the single letter code and their
position is indicated according to the EU-index numbering
[16].
The Hinge and CH2 Domains Are Responsible for Poor
Binding to C1q and FcγRs
The structure of IgG4 combines a short hinge and low Fab-
arm flexibility [17]. Since the composition and length of the
hinge affects the conformation and the flexibility of the Fab
arms relative to each other, and relative to the Fc region, the
orientation of the IgG4 Fab arms may partly shield the C1q
and FcγR binding sites on the CH2 domain [18, 19].
Together with the lower hinge region, the FG loop (loop
between strand F and strand G) from the CH2 domain is also
known to be crucial for IgG binding to FcγRs [20, 21] and to
C1q [22, 23]. Recent high resolution crystal structures of
human IgG4-Fc showed that the FG loop in the IgG4 CH2
domain can adopt a unique conformation that disrupts the
C1q and FcγR binding sites [24••] (Fig. 1a).
These features combined could be responsible for the poor
ability of IgG4 to engage C1q and FcγRs and could result in
low capacity to trigger effector functions.
Fab-arm Exchange Affects Bivalency
A distinct property of IgG4 is its ability to undergo a process
termed Fab-arm exchange, in which Bhalf molecules,^ each
comprising one heavy and one light chain (HL), exchange
with IgG4 antibodies of different specificities, resulting in
the formation of bi-specific antibodies [15]. FAE has been
demonstrated to occur in vivo [25, 26].
Structurally, the two half HL molecules are held together by
covalent (hinge disulfide bonds) and non-covalent (CH3-CH3)
interactions. Two features, namely the core hinge sequence and
residue 409 at the CH3-CH3 domain interface, which both
weaken the interactions between the two half HL molecules,
are responsible for the ability of IgG4 to undergo FAE (Fig. 1a).
In IgG1, which does not undergo FAE, residues 226–229 in
the core hinge have a Cysteine-Proline-Proline-Cysteine
(CPPC) sequence motif. On the other hand, the IgG4 core
hinge has a Cysteine-Proline-Serine-Cysteine (CPSC) motif.
The IgG4 core hinge is believed to be more flexible, promot-
ing the formation of intra-heavy chain disulfide bonds, Thus,
two hinge isomers are possible, one with the typical inter-
heavy chain disulfide bonds (covalently linked half mole-
cules), and the other with intra-heavy chain disulfide bonds
(non-covalently linked half molecules) [26, 27] (Fig. 1a). The
S228P mutation, which renders the IgG4 core hinge more
IgG1-like, abolishes the formation of intra-chain disulfide
bond isomers and abrogates FAE in vitro and in vivo [26, 27].
Additionally, the IgG4 CH3 domain differs from the IgG1
CH3 domain in that lysine 409 in IgG1 is substituted for argi-
nine in IgG4 (Fig. 1a). Residue 409 is located at the interface
between the CH3 domain dimer. Arg409 disrupts the inter-
domain network of water-mediated hydrogen bonds that is
conserved in IgG1 and weakens the non-covalent interaction
between the CH3 domains [28, 29••].
A direct consequence of Fab-arm exchange is the production
of IgG4 antibodies with randomdual specificity, unable to cross-
link identical antigens and therefore perhaps unable to form
large IC against a specific target. For this reason, such IgG4
molecules may be defined as functionally monovalent [30, 31].
A different interpretation of FAE may be that bispecificity,
the ability to bind two antigens, is a property that might increase
the avidity of the antibody if these antigens are proximally lo-
cated on target cells [32]. If bi-specific IgG4 could crosslink two
different antigens, for instance on the surface of a tumor cell, the
effects of these interactions are far from clear, and these interac-
tions might promote or restrict target cell signaling and growth.
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ATemporal Model for Isotype Switching: Potential
Implications for Higher Antigen Affinities for IgG4
An analysis of almost 1000 VDJ sequences extracted from B
cells of individuals living in an area of endemic parasitism
showed a positive correlation between the number of muta-
tions somatic hypermutation (SHM) and the distance of the
specific Cγ gene from the VDJ region in the heavy chain
locus. The Cγ4 locus is the last of the IgG subclasses on
chromosome 14 [33••]. The authors proposed a temporal
model, where CSR occurred sequentially from IgM to IgG3
then to IgG1, to IgG2, and finally to IgG4, with the implica-
tion that class-switched IgG4 B cells would be the last to exit
from germinal centers. Since AID is involved both in CSR and
SHM, B cells would also accumulate mutations in the VDJ
region, leading to the production of antibodies with higher
affinity (affinity matured) [32]. Most activating immune re-
sponses induce the rapid production of IgG3 and IgG1, but not
of the other isotypes, possibly due to the rapid elimination of
the antigen-expressing targets. However, if the antigen per-
sists, B cells continue to be activated in the germinal centers
and undergo sequential CSR to IgG2 and IgG4.
Notably, the Cγ position on heavy chain locus and there-
fore the extent of SHM, also positively correlate with antibody
effector functions (lower ability to activate complement and
FcγRs for IgG2 and IgG4). This could be interpreted as a
mechanism of self-regulation by the immune system to avoid
self-damage in response to a chronic antigenic stimulus. Ac-
cording to the CSR temporal model, IgG4 has higher affinity
for antigen compared to IgG1 or IgG3, while it also has poor
capacity to activate complement and FcγRs. Evidence to sup-
port this model exists in the context of allergy [34] and of
endemic parasitism [32, 33••].
In cancer, high-affinity tumor-specific IgG4 could compete
with IgG1 for the binding to tumor-associated antigens. Since
IgG4 has lower ability to trigger effector functions compared
to IgG1, this competition results in reduced antibody-
mediated effector functions and escape from the immune
surveillance.
Evidence for an IgG4 Bias in Some Tumors
IgG4 is usually the least-represented IgG subclass in human
serum, comprising less than 4 % of the total IgG, but high
IgG4 levels can occur in particular conditions, usually follow-
ing repeated or chronic exposure to an antigen. Elevated levels
of IgG4 in tissues and in serum are associated with inflamma-
tion in a range of chronic pathological conditions, such as
rheumatoid arthritis [35], IgG4-related diseases (IgG4-RD)
[36], and pemphigus vulgaris [37]. Elevated levels of
IgG4 are also associated with immune tolerance under
conditions of chronic exposure to a specific antigen,
such as tolerance to bee venom in beekeepers [38•] or
reduced allergic symptoms after allergen-specific immu-
notherapy in atopic individuals [14, 39].
IgG4 responses have also been reported in different cancers
such as melanoma [40, 41••, 42••], extrahepatic cholangiocar-
cinoma [43, 44], pancreatic cancer [45], and glioblastoma
[46••].
Tumor lesions are pathological conditions which present
features resembling chronic inflammation. Some of these fea-
tures may be (a) formation of tertiary lymphoid structures,
shown to contain functional germinal centers [47•] where
antigen-driven antibody responses may occur [48, 49] and
(b) infiltration of M2-type macrophages and Foxp3+ regulato-
ry Tcells (Treg cells). IgG4 antibodies and IgG4+ B cells were
detected together with Tregs in the tumor microenvironment
of pancreatic cancer, cholangiocarcinoma [50], and melanoma
lesions [41••, 51]. These tumor types were also characterized
by Th2-biased environments with local expression of IL-10,
IL-4, VEGF [41••], and TGF-β [50], mediators known to
trigger B cells to produce IgG4 (Fig. 1b). IgG4 was found to
positively correlate with Tregs and to negatively correlate with
cytotoxic T lymphocytes [50], supporting its involvement of
immune tolerance in cancer. Furthermore, ex vivo studies sug-
gested that melanoma and B cell cross-talk can trigger elevat-
ed expression of IL-10 and VEGF, inducing B cells to produce
IgG4 [41••]. Several carcinomas and cancer cell lines are
found to produce IL-10 and FoxP3 [52], indicating that tu-
mors may promote a biased Th2 response which supports
IgG4, re-educating host immune responses and escaping the
immune clearance. Consistent with this, elevated serum IgG4
levels have been associated with poorer prognosis in biliary
tract cancers [43] and in malignant melanoma [41••, 42••].
Whether any tumor-associated IgG4 antibodies are tumor
reactive is still unclear, although early evidence suggests this
may be true in malignant melanoma [41••] and glioblastoma
[46••]. Supernatants from ex vivo cultured B cells, isolated
from melanoma patient blood and lesions, showed reactivity
against melanoma cells in a cell-based ELISA [53], even if
further analysis will be required to assess the specificity for
tumor-associated antigens and exclude an allo-reactivity. Fur-
thermore, tumor-exosome-reactive IgG4 and IgG2 antibodies
were found in sera from glioblastoma patients [46••]. In other
diseases, such as rheumatoid arthritis, IgG antibodies, includ-
ing IgG4, were found to be specific for citrullinated fibrin and
used as a serological marker [54]. On the other hand, in dis-
eases such as IgG4-RD, IgG4 antibodies are usually found to
be unspecific to disease-associated or auto-antigens [36]. Fur-
thermore, only a small proportion of circulating IgG4 antibod-
ies has been shown to recognize the specific allergen in atopic
patients following allergen immunotherapy [55]. Thus, addi-
tional research would be required to ascertain the tumor reac-
tivity and antigen specificity of tumor-associated IgG4 in pa-
tients with cancer.
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IgG4 Anti-inflammatory Properties: Blockade
of IgG1-Mediated Effector Functions in Some
Disease Settings Including Cancer
Evidence in different disease settings points to the ability of
IgG4 to impair the effector functions of other immunoglobu-
lins such as IgG1. In an in vivo model of myasthenia gravis, it
was shown that IgG4 prevented IgG1-mediated internaliza-
tion and degradation of acetylcholine receptors (AchRs)
[25]. In human melanoma xenograft models in mice, partly
reconstituted with human immune effector cells, tumor
antigen-specific IgG4 could inhibit IgG1-mediated restriction
of subcutaneous tumor growth [41••].
IgG4 could exert its inhibitory functions binding through
the Fab (tumor-specific IgG4) or binding through the Fc (un-
specific IgG4). The potential mechanisms by which IgG4 can
interfere with the immune activating functions of IgG1 and of
other class antibodies such as IgE are discussed below.
IgG4 Competes with IgG1 for the Binding to the Antigen
but Has Poor Ability to Trigger Effector Functions
The affinity of IgG4 for FcγRI is of the same order of mag-
nitude as that of IgG1, while its affinities for FcγRIIa and
FcγRIIIa are much lower than those of IgG1. FcγRs
expressed on immune effector cells are engaged by antibodies
to trigger antibody-dependent cellular phagocytosis (ADCP)
and antibody-dependent cellular cytotoxicity (ADCC).
FcγRIIa expressed on macrophages and phagocytes is in-
volved in ADCP [56], while FcγRIIIa is expressed on NK
cells and plays a crucial role in ADCC [57]. For this reason,
even if IgG4 is able to bind FcγRI, the poor affinity to the
other activating receptors may result in lower potency to me-
diate ADCC [58–61], and ADCP compared to IgG1. In gen-
eral, IgG4 effector function could depend on the relative ex-
pression of FcγRs on the effector cells. Furthermore, unlike
IgG1, IgG4 is not able to trigger complement-dependent cy-
totoxicity (CDC) [59].
In a scenario where IgG4 competes with IgG1 for the bind-
ing to the antigen, the poor effector function of IgG4 could
result in the blocking of the potential IgG1-mediated effect
(Fig. 1b).
There are mainly two mechanisms by which IgG4 could
compete with IgG1 for the binding to the tumor. Firstly, ac-
cording to CSR temporal model, IgG4 antibodies developed
in the lesion should have higher affinity for the target antigen
compared with IgG1, therefore competing for the binding to
the tumor cells. The second is based on the theory that FAE is
a mechanism that could, in certain conditions, increase IgG4
avidity to the antigen. Bi-specific IgG4 antibodies, able to
simultaneously bind to the same or related antigens on target
cells, are unlikely if Fab-arm exchange occurs in the blood
stream with other IgG4 antibodies of unrelated specificity
[25]. However, this might occur if clonally related antibodies
against the same antigen or antibodies against different anti-
gens on the same target cells co-localize at a site of inflamma-
tion [32], such as in tumor microenvironments.
High-affinity IgG4 Can Take Part in IgG1 IC
Co-engaging FcγRIIb with Activating FcγRs
Another possible mechanism of action of IgG4 could be me-
diated through the binding to the inhibitory receptor FcγRIIb.
There is evidence that IgG4 can bind FcγRIIb with higher
affinity than other IgG subclasses (Table 1) [12]. FcγRIIb is
known to play a crucial role in regulating both innate (macro-
phage, mast cell, and basophil activation) and adaptive immu-
nity (DC activation and antigen cross-presentation). It is also
involved in B cell and plasma cell fate during the immune
response [62]. Since FcγRIIb is able to exert its inhibitory
action only if co-engaged with activating FcγRs [25], it has
been speculated that high-affinity IgG4 could form ICs togeth-
er with other antibodies, such as IgG1, and co-engage both
FcγRIIb and activating FcγRs, thus dampening FcγR-
mediated processes (Fig. 1b). According to this hypothesis,
IgG4 might be able to exert an inhibitory effect even if its
concentration is lower than IgG1 [32].
IgG4 Can Bind IgG1 via Fc-Fc Interactions
IgG4 has been shown to bind other IgGs, in particular IgG1,
via Fc-Fc interactions [63, 64••]. Two crystal structures of
IgG4-Fc show two interfaces for Fc-Fc interactions localized
in IgG4 CH2 and CH3 domains. Residues from these two
interfaces belong to a consensus binding site for Fc-binding
proteins such as neonatal Fc receptor (FcRn), TRIM21 [65],
rheumatoid factor, staphylococcal protein A, streptococcal
protein G, and the Herpes simplex virus type 1 (HSV-1) gE-
gI receptor [66], and some residues also belong to
aggregation-prone motifs [67]. The Fc-Fc interactions ob-
served in the IgG4-Fc crystal structures may provide a model
for the tendency of IgG4 to aggregate [24••]. Indeed, a study
of therapeutic monoclonal antibodies showed that IgG4 has a
higher tendency to aggregate than IgG1 [68].
A rheumatoid factor-like activity of IgG4 was observed
first in rheumatoid arthritis [69, 70] and recently in autoim-
mune pancreatitis [71]. IgG4-Fc and not Fab was found to
bind the heavy chain of all IgG1 subclasses [71]. Furthermore,
Fc-Fc interaction was demonstrated between IgG4 and
conformationally altered IgG4 or IgG1 immobilized on a
solid-phase [63]. It was furthermore shown that IgG4 Fc-Fc
interactions require partial dissociation of the IgG heavy
chains [64••]. The authors hypothesized that IgG4 could act
as a scavenger, by binding to IgG fragments and preventing
their unfolding and formation of aggregates [64••].
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Tumor microenvironments are rich in proteases such
as matrix metalloproteases (MMP), which support extra-
cellular matrix degradation, tissue remodeling, and pro-
motion of cancer cell metastasis. An additional effect of
these enzymes may be to partly dissociate or cleave
host-produced or therapeutic antibodies [72]. An associ-
ation between an inflammatory environment and the
cleavage of autoantibodies was also found in rheuma-
toid arthritis [73]. In vitro studies showed that microbial
origin and tumor-related proteases are also able to
cleave IgG1 in a conserved region at the lower hinge/
CH2 interface. Full cleavage to F(ab′)2 fragments is pre-
ceded by an intermediate with one intact heavy chain
[74]. The same authors reported cleaved antibodies in
breast cancer tumor extracts and suggested that cleaved
IgG antibodies are likely present in tumor microenviron-
ments. The cleaved antibodies have impaired FcR bind-
ing and effector functions but comparable antigen-
binding capacity to that of intact antibodies. These dam-
aged antibodies could therefore compete for the binding
to the antigen and block the functional effects of un-
damaged IgGs [74], suggesting that proteolytic activity
in tumor microenvironments could impair IgGs as a
possible mechanism of tumor escape from host immune
surveillance [72, 74].
In the proteolytic conditions of a tumor microenvironment,
with cleaved IgG1 antibodies bound to tumor antigens, the
cleavage of one of the heavy chains at the junction between
the lower hinge and the CH2 domain may cause a partial
dissociation of the cleaved heavy chain from the rest of the
antibody. The partly dissociated IgG1 could facilitate the bind-
ing of IgG4-Fc resulting in the blockade, via Fc-Fc interac-
tions, of single-chain cleaved IgG1 on the surface of tumor
cells (Fig. 1b). This would probably require a high local con-
centration of IgG4 to overcome the affinity of the IgG1-Fc
region for Fcγ receptors. However, the concentration of im-
munoglobulins in tumors is currently unknown. Fc-Fc medi-
ated interactions could potentially interfere with IgG1-
mediated effector functions or result in intracellular uptake
and clearance of the target from the tumor cell surface.
Implications of Employing IgG4 Subclass Antibodies
in Cancer Immunotherapy
Passive Immunotherapy
IgG4, together with IgG2, is the preferential subclass in
the design of therapeutic antibodies, when the recruitment
of the immune cells is undesired (receptor-blocking
antibodies) or unnecessary (payload delivery antibodies)
[75]. Therapeutic IgG4s can undergo FAE with endoge-
nous IgG4. Depending on the mechanism of action of
each specific therapeutic antibody, hinge stabilization
(S228P mutation) could be a design consideration to
prevent FAE in vivo [26].
IgG4 is generally considered an anti-inflammatory anti-
body due to its functionally monovalent properties, its
poor ability to bind C1q and the activating low-affinity
FcγRs. Nevertheless, IgG4 binds FcγRI with a KA of
the same order of magnitude as IgG1 and IgG3, and the
inhibitory FcγRIIb receptor with higher affinity than the
other subclasses [12, 76]. Thus in principle, it may be
able to trigger effector functions. To eliminate any residual
effector functions, therapeutic IgG4 antibodies can be
engineered with mutations (such as L235E) that abrogate
FcγR interactions [77, 78].
The overall anti-inflammatory activity of IgG4s, de-
spite their affinity for FcγRI, could be related to their
functional monovalency [15]. Therapeutic IgG4s carrying
the S228P mutation are monospecific due to their inability
to undergo FAE and would be able to crosslink antigens and
to form small or large ICs. Large IgG4-ICs are able to
bind the activating low-affinity FcγRs [79]. For this rea-
son, during the design of IgG4 therapeutic antibodies, it
may be important to incorporate both mutations that sta-
bilize the hinge and those that completely abrogate Fcγ recep-
tor binding.
Active Immunotherapy
Triggering a patient response against cancer may be a desirable
feature of active cancer immunotherapy. The emerging field
known as AllergoOncology includes the use of IgE antibodies
and antibody responses in cancer therapy [80]. IgE class
switching may occur in a relatively naïve IgM-secreting B cell
(direct route) or in an isotype-switched IgG4-expressing B cell
(indirect route) [81]. In a clinical context, where the tumor
lesion is infiltrated with IgG4+ B cells expressing high-
affinity tumor antigen-specific IgG4s [41••], a valid tool for
active immunotherapy could be the implementation of immu-
nization approaches that support tumor-localized isotype
switching from IgG4 to more potent IgE antibodies, via the
indirect route. The result may be in situ production, of tumor
antigen-specific IgE with high affinity for tumor targets that
could mediate potent ADCC and ADCP against tumor cells
and restrict tumor progression. Alternative approaches
such as treatment with engineered IgE antibodies against
cancer antigens may activate effector cells by signaling
through IgE Fc receptors, as a means of bypassing IgG4-
mediated Fc blockade mechanisms. In the last decade,
mounting evidence supports the idea of engineering IgE
antibodies and vaccination approaches that result in IgE-
biased immune responses against cancer as powerful
tools for cancer immunotherapy [82–85].
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Conclusion
The structural and functional attributes of IgG4 de-
scribed here render it unique among the IgG subclasses.
Its ability to undergo FAE may be only partly respon-
sible for its low affinity for activating receptors
expressed on immune effector cells and consequently
low capacity to engage these cells to trigger ADCP
and ADCC and also for its poor ability to bind C1q
and fix complement. IgG4 is considered an antibody
with low immunoactivatory properties, and it is a suit-
able subclass for the design of therapeutic antibodies
when effector functions are not desirable. However, a
better understanding of its properties and functions
in vivo is still required to inform the design and opti-
mization of IgG4-based therapeutic antibodies. Reports
of IgG4 antibodies and IgG4+ B cells in different can-
cers suggest the involvement of IgG4 in tumor escape
from immune surveillance through a number of potential
mechanisms, including IgG4 blockade of IgG1-mediated
effector functions. However, IgG4 and its roles in can-
cer inflammation remain unclear. Dissecting the cross-
talk between cancer and humoral immunity and the con-
ditions that can promote IgG4-biased Bregulatory^ re-
sponses can inform the design of novel therapeutic antibod-
ies with improved immune activatory and effector functions
and reduced susceptibility to tumor-associated immune
blockade.
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